London, UK, 6 OCTOBER 2023
We are delighted to announce that our latest clinical trial ‘RESP30X-EBA’ is active and recruiting at the TASK Clinical Research Centre, South Africa. The first group of participants have been screened and four patients have already been dosed only a week into the study’s official launch. This is an important milestone for the company as we tackle a disease which is one of the world’s top infectious killers.
About RESP30X-EBA
RESP30X-EBA is a Phase 2 Early Bactericidal Activity trial in adults with newly diagnosed pulmonary tuberculosis (TB). We are excited to be collaborating with the team at TASK-South Africa who are performing full-service oversight of the study on our behalf.
About Tuberculosis
TB infects 10 million people and results in 1.5 million deaths a year, despite being a preventable and curable disease.